ID
BIS icon

Integral Derivatives’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Integral Derivatives’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,863
Closed -$658K – 1097
2015
Q2 		$658K Buy
+2,863
New +$710K 0.02% 649

Other funds holding BIS

HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CAM
Chesapeake Asset Management New York $126M AUM 36.76% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Integral Derivatives's BIS Position: Q3 2015 in Review

Integral Derivatives sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q3 2015, closing a stake of 1,388 shares — an estimated $319K sold.

Integral Derivatives first reported a position in BIS in Q3 2014 and held it in 2 quarters. The position peaked at $319K in Q2 2015. 19 funds tracked by Wall St. Rank hold BIS as of Q3 2015.

  • Integral Derivatives reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q3 2015 after selling out during the quarter.
  • Integral Derivatives sold 1,388 ProShares UltraShort NASDAQ Biotechnology shares in Q3 2015, an estimated $319K.
  • Integral Derivatives first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q3 2014 and held it in 2 quarters.
  • Integral Derivatives's ProShares UltraShort NASDAQ Biotechnology position peaked at $319K in Q2 2015.
  • 19 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q3 2015.

Based on Integral Derivatives's 13F filing for Q3 2015, filed 15 Oct 2015.